Actifed

Actifed is an over-the-counter medicine brand used to relieve nasal symptoms associated with the common cold and allergies. Its traditional product concept combines an antihistamine, intended to reduce symptoms such as runny nose and sneezing, with a nasal decongestant intended to reduce congestion. The brand was developed in 1958 by Burroughs Wellcome & Company, a pharmaceutical company that subsequently became part of GlaxoSmithKline and whose consumer-health brands were later associated with Haleon. Actifed has not represented one globally uniform medicine. Formulations, dosage strengths, indications, pack sizes, legal classifications, and marketing companies have differed by country. The classic formulation used pseudoephedrine hydrochloride as the decongestant and triprolidine hydrochloride as the antihistamine. In the United Kingdom, Germany, and Italy, the reference material identifies the traditional combination as remaining available, including a McNeil-produced 12-tablet pack containing triprolidine hydrochloride 2.5 mg and pseudoephedrine hydrochloride 60 mg per tablet. In Germany, the product is marketed under the registered trademark RhinoPRONT. The United States formulation changed in late 2006. Pfizer replaced pseudoephedrine and triprolidine with phenylephrine hydrochloride and chlorpheniramine maleate in response to legal requirements that products containing pseudoephedrine be kept behind the pharmacy counter. The change occurred before the brand was reacquired by GlaxoSmithKline. The reformulated American product used phenylephrine hydrochloride 10 mg and chlorpheniramine maleate 4 mg. Some consumers considered the replacement less effective than the earlier formulation. In 2023, a U.S. Food and Drug Administration advisory panel concluded that orally administered phenylephrine was ineffective as a nasal decongestant, adding regulatory and scientific scrutiny to products using that ingredient. The brand has also had a notable association with human spaceflight. Actifed was included in the standard medical kits used on United States Apollo missions and was reportedly used during Apollo 7 and Apollo 12 when crew members developed cold symptoms. Former Apollo astronauts later appeared in Actifed advertising after the medicine became available over the counter. Availability has changed by market. Thailand withdrew Actifed from sale in 2012 after pseudoephedrine-containing medicines became subject to strict control under the country's narcotics-control framework. In the United States, Walgreens sold a house-brand equivalent called Wal-Act that used the older pseudoephedrine-and-triprolidine combination; in 2021, Walgreens renamed that product Cold & Allergy D while retaining the same active-ingredient combination. These market-specific developments illustrate why Actifed's composition and status should be checked against local packaging and regulatory information rather than inferred solely from the brand name.

Actifed originated in 1958 as a medicine developed by Burroughs Wellcome & Company. The brand was designed around a combination of two therapeutic functions: an antihistamine to address symptoms such as runny nose and sneezing, and a nasal decongestant to reduce congestion. Its traditional formulation used triprolidine hydrochloride 2.5 mg together with pseudoephedrine hydrochloride 60 mg per tablet. This combination became the basis for Actifed products in several markets, although the brand's composition and regulatory status have never been completely uniform worldwide. Burroughs Wellcome later became part of GlaxoSmithKline. The Actifed brand subsequently became associated with the consumer-health business that was separated from GSK as Haleon. Ownership and marketing arrangements have varied by market, and some regional products have been manufactured or marketed by different operating companies. In Germany, the equivalent product is marketed under the registered trademark RhinoPRONT. Actifed also acquired an unusual place in popular and commercial history through the United States space program. The medicine was included in medical kits aboard Apollo missions and was used during Apollo 7 and Apollo 12 when astronauts developed head-cold symptoms. After Actifed became available without a prescription, former Apollo astronauts appeared in advertisements for the product, linking its consumer marketing with its use in spaceflight medical kits. A major turning point occurred in the United States in late 2006. Restrictions requiring pseudoephedrine products to be kept behind the pharmacy counter prompted Pfizer to alter the American Actifed formula. The revised product replaced pseudoephedrine hydrochloride with phenylephrine hydrochloride and replaced triprolidine hydrochloride with chlorpheniramine maleate. The new formulation contained phenylephrine hydrochloride 10 mg and chlorpheniramine maleate 4 mg. The change took place before the brand was reacquired by GlaxoSmithKline. Consumers familiar with the earlier product often criticized the replacement as less effective. The change did not occur in every market. Reference material identifies the United Kingdom, Germany, and Italy as retaining the traditional pseudoephedrine-and-triprolidine formulation, including a McNeil-produced 12-tablet pack in those markets. In Thailand, however, Actifed was withdrawn from sale in 2012 after pseudoephedrine-containing medicines came under strict control under narcotics legislation. The U.S. formulation later faced additional scrutiny because of its use of oral phenylephrine. In 2023, an FDA advisory panel concluded that orally administered phenylephrine was ineffective as a nasal decongestant. This finding did not erase the brand's historical identity, but it highlighted the importance of distinguishing between regional Actifed formulations. Walgreens maintained a house-brand product using the older pseudoephedrine-and-triprolidine combination. That product was renamed from Wal-Act to Cold & Allergy D in 2021. Today, Actifed should be understood as a geographically variable medicine trademark rather than a single globally identical product. Its historical significance rests on its long-running cold-and-allergy positioning, its reformulation in the United States, the regulatory consequences of pseudoephedrine controls, and its association with Apollo-era medical supplies.

• 2023

  FDA panel reviewed oral phenylephrine

  [1]Actifeden.wikipedia.org

  An FDA advisory panel concluded that oral phenylephrine was ineffective as a nasal decongestant.

• 2021

  Wal-Act renamed Cold & Allergy D

  [1]Actifeden.wikipedia.org

  Walgreens renamed its house-brand equivalent while retaining the older active-ingredient combination.

• 2012

  Thai-market withdrawal

  [1]Actifeden.wikipedia.org

  Actifed was withdrawn in Thailand after pseudoephedrine medicines became tightly controlled.

• 2006

  United States formulation changed

  [1]Actifeden.wikipedia.org

  The American product moved from pseudoephedrine and triprolidine to phenylephrine and chlorpheniramine in response to restrictions on pseudoephedrine sales.

• 1969

  Actifed used during Apollo 12

  [1]Actifeden.wikipedia.org

  The medicine was reportedly used during Apollo 12 after crew members experienced cold symptoms.

• 1968

  Actifed used during Apollo 7

  [1]Actifeden.wikipedia.org

  Actifed was reportedly used when Apollo 7 crew members developed head-cold symptoms.

• 1958

  Actifed developed by Burroughs Wellcome

  [1]Actifeden.wikipedia.org

  Burroughs Wellcome & Company developed Actifed as a combination antihistamine and nasal-decongestant medicine.

Over-the-counter cold and allergy symptom relief, particularly for nasal congestion and runny nose.

• Over-the-counter cold and allergy medicine · 1958

  Traditional Actifed tablets

  The traditional Actifed tablet combined pseudoephedrine hydrochloride 60 mg, a nasal decongestant, with triprolidine hydrochloride 2.5 mg, an antihistamine. This formulation was associated with the brand in several markets, including the United Kingdom, Germany, and Italy. Pack sizes, legal status, labeling, and availability vary by country.

• Over-the-counter cold and allergy medicine · 2006

  United States Actifed reformulation

  The United States version introduced in late 2006 used phenylephrine hydrochloride 10 mg as the decongestant and chlorpheniramine maleate 4 mg as the antihistamine. It replaced the earlier pseudoephedrine-and-triprolidine formula after restrictions on pseudoephedrine sales. The product later became relevant to debate over the effectiveness of oral phenylephrine.

• Regional registered-trademark medicine

  RhinoPRONT

  In Germany, the Actifed product is marketed under the registered trademark RhinoPRONT. The reference material identifies the German formulation as retaining the traditional triprolidine-and-pseudoephedrine combination.

• Apollo astronaut advertising

  United States

  After Actifed became available over the counter, former Apollo astronauts appeared in advertising for the medicine. The campaign used the product's inclusion in Apollo medical kits and reported use during missions as a credibility and reassurance message.

  Outcome. The advertising connected Actifed with the Apollo space program and helped make its spaceflight association part of the brand's public identity.

  Source

• 2021

  Wal-Act brand renamingOther

  Background

  Walgreens sold a house-brand product using the older pseudoephedrine-and-triprolidine combination associated with traditional Actifed.

  Action taken

  Walgreens changed the product name from Wal-Act to Cold & Allergy D.

  Aftermath

  The active-ingredient combination remained unchanged after the renaming.

  Source

• 2012

  Withdrawal from ThailandStrategy

  Background

  Thailand imposed strict controls on pseudoephedrine-containing medicines under its narcotics-control framework.

  Action taken

  Actifed was withdrawn from the Thai market.

  Aftermath

  The brand was no longer available in Thailand according to the reference material.

  Source

• 2006

  United States Actifed reformulationGeneration change

  Background

  U.S. rules required products containing pseudoephedrine to be kept behind the pharmacy counter, creating a commercial and regulatory incentive to change the formula.

  Action taken

  Pfizer replaced pseudoephedrine hydrochloride and triprolidine hydrochloride with phenylephrine hydrochloride 10 mg and chlorpheniramine maleate 4 mg in the United States.

  Aftermath

  Many users reported that the replacement was less effective. The reformulation was also affected by the later FDA advisory-panel finding concerning oral phenylephrine.

  Source

1. 1Actifeden.wikipedia.org
2. 2Actifed informationdrugs.com